TriSalus Life Sciences Files 8-K on Financials
Ticker: TLSIW · Form: 8-K · Filed: Feb 3, 2025 · CIK: 1826667
| Field | Detail |
|---|---|
| Company | Trisalus Life Sciences, Inc. (TLSIW) |
| Form Type | 8-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, company-update
TL;DR
TriSalus Life Sciences dropped its 8-K, check the financials for Jan 31, 2025.
AI Summary
TriSalus Life Sciences, Inc. filed an 8-K on February 3, 2025, reporting on its financial condition and results of operations as of January 31, 2025. The filing includes financial statements and exhibits related to the company's fiscal year-end. TriSalus Life Sciences, formerly known as MedTech Acquisition Corp, is incorporated in Delaware and operates in the surgical and medical instruments sector.
Why It Matters
This 8-K filing provides an update on TriSalus Life Sciences' financial status, which is crucial for investors to assess the company's performance and make informed decisions.
Risk Assessment
Risk Level: low — This filing is a routine financial disclosure and does not indicate any immediate or significant risks.
Key Players & Entities
- TriSalus Life Sciences, Inc. (company) — Registrant
- MedTech Acquisition Corp (company) — Former name
- January 31, 2025 (date) — Reporting period end date
- February 3, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of TriSalus Life Sciences, Inc., as of January 31, 2025.
When was TriSalus Life Sciences, Inc. previously known?
TriSalus Life Sciences, Inc. was formerly known as MedTech Acquisition Corp, with a date of name change on September 30, 2020.
What is the principal executive office address for TriSalus Life Sciences, Inc.?
The principal executive office address for TriSalus Life Sciences, Inc. is 6272 W 91st Ave, Westminster, Colorado 80031.
What is the SIC code for TriSalus Life Sciences, Inc.?
The Standard Industrial Classification (SIC) code for TriSalus Life Sciences, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
What is the fiscal year end for TriSalus Life Sciences, Inc.?
The fiscal year end for TriSalus Life Sciences, Inc. is December 31 (1231).
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-02-03 11:08:52
Key Financial Figures
- $0.0001 — ange on which registered Common stock, $0.0001 par value TLSI Nasdaq Global Market
- $11.50 — 's common stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Market
Filing Documents
- tlsi-20250131.htm (8-K) — 28KB
- trisaluslifesciencespr-202.htm (EX-99.1) — 12KB
- imagea.jpg (GRAPHIC) — 20KB
- 0001826667-25-000014.txt ( ) — 237KB
- tlsi-20250131.xsd (EX-101.SCH) — 2KB
- tlsi-20250131_def.xml (EX-101.DEF) — 16KB
- tlsi-20250131_lab.xml (EX-101.LAB) — 27KB
- tlsi-20250131_pre.xml (EX-101.PRE) — 16KB
- tlsi-20250131_htm.xml (XML) — 4KB
02 Results of Operations and Financial Conditions
Item 2.02 Results of Operations and Financial Conditions. On February 3, 2025, TriSalus Life Sciences, Inc. (the "Company") announced a requested drawdown under the Company's Credit Agreement with OrbiMed, a healthcare investment firm, in the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after today's date, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release date February 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 3, 2025 TriSalus Life Sciences, Inc. By: /s/ James Young Name: James Young Title: Chief Financial Officer